Effectiveness and Safety of Selective IL-23 Receptor Antagonists in Moderate to Severe Ulcerative Colitis: A Systematic Review, Meta-Analysis and Trial Sequential Analysis
Preprint
Abstract
Selective interleukin-23 receptor antagonists (IL-23RA) show promise for treating moderate to severe ulcerative colitis (UC) but their efficacy and safety are not fully understood. We performed a systematic review and meta-analysis of randomized controlled trials comparing IL-23RA with placebo in moderate to severe UC. Outcomes included clinical and endoscopic remission, response rates, and adverse events. Nine trials including 3808 patients in the induction phase and 1734 in the maintenance phase were analyzed. IL-23RA improved clinical remission (induction risk ratio 2.63, 95 percent confidence interval 2.05-3.36; maintenance 1.99, 95 percent confidence interval 1.63-2.44) and endoscopic remission (induction 2.36, 95 percent confidence interval 1.70-2.20; maintenance 1.96, 95 percent confidence interval 1.63-2.37). IL-23RA reduced serious adverse events in the induction phase (0.40, 95 percent confidence interval 0.27-0.69) with no difference during maintenance (0.75, 95 percent confidence interval 0.31-1.84). No significant differences were observed in overall adverse events or specific events such as headache or nasopharyngitis. Trial sequential analysis confirmed sufficient sample size for clinical endpoints. IL-23RA showed superior effectiveness and similar safety compared with placebo in moderate to severe UC.Keywords
All Related Versions
This publication has 29 references indexed in Scilit:
- Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studiesThe Lancet, 2024
- Comparative Efficacy of Biologics and Small Molecule in Ulcerative Colitis: A Systematic Review and Network Meta-analysisClinical Gastroenterology and Hepatology, 2024
- Targeting IL-23 for IBD: Rationale and Progress to DateDrugs, 2023
- IL-12 and IL-23 pathway inhibition in inflammatory bowel diseaseNature Reviews Gastroenterology & Hepatology, 2023
- Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysisThe Lancet Gastroenterology & Hepatology, 2022
- Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel DiseaseBioDrugs, 2020
- Risk‐of‐bias VISualization (robvis): An R package and Shiny web app for visualizing risk‐of‐bias assessmentsResearch Synthesis Methods, 2020
- Evolving therapeutic goals in ulcerative colitis: towards disease clearanceNature Reviews Gastroenterology & Hepatology, 2019
- Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analysesJournal of Clinical Epidemiology, 2008
- Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysisJournal of Clinical Epidemiology, 2008